Stryker Corporation (SYK) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Stryker Corporation stock (SYK) is currently trading at $327.65. Stryker Corporation PE ratio is 39.06. Stryker Corporation PS ratio (Price-to-Sales) is 5.01. Analyst consensus price target for SYK is $424.18. WallStSmart rates SYK as Hold.
Stryker Corporation (SYK) stock price prediction for 2030: Base case $217.86. Bull case $272.32. Bear case $163.39. See full SYK 2030 price forecast and methodology on WallStSmart.
- SYK PE ratio analysis and historical PE chart
- SYK PS ratio (Price-to-Sales) history and trend
- SYK intrinsic value — DCF, Graham Number, EPV models
- SYK stock price prediction 2025 2026 2027 2028 2029 2030
- SYK fair value vs current price
- SYK insider transactions and insider buying
- Is SYK undervalued or overvalued?
- Stryker Corporation financial analysis — revenue, earnings, cash flow
- SYK Piotroski F-Score and Altman Z-Score
- SYK analyst price target and Smart Rating
Stryker Corporation
📊 No data available
Try selecting a different time range
SYK Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Stryker Corporation (SYK)
SYK appears undervalued based on the Graham Formula, trading 17% below its estimated fair value of $393.59.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Stryker Corporation (SYK) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, eps growth. Concerns around price/book. Fundamentals are solid but monitor weak areas for improvement.
Stryker Corporation (SYK) Key Strengths (5)
Earnings per share surging 55.90% year-over-year
82.23% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $27 kept per $100 revenue
Solid profitability: $15 profit per $100 equity
Supporting Valuation Data
Stryker Corporation (SYK) Areas to Watch (5)
Very expensive at 5.7x book value
Premium valuation at 5.0x annual revenue
Growth is fairly priced, not cheap, not expensive
Solid revenue growth at 11.40% per year
Decent profitability, keeps $13 per $100 revenue
Supporting Valuation Data
Stryker Corporation (SYK) Detailed Analysis Report
Overall Assessment
This company scores 65/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 8.8/10) while 5 fall into concern territory (avg 4.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own., Market Cap. Profitability is solid with Return on Equity at 15.10%, Operating Margin at 27.20%. Growth metrics are encouraging with EPS Growth at 55.90%.
The Bear Case
The primary concerns are Price/Book, Price/Sales, PEG Ratio. Some valuation metrics including PEG Ratio (1.60), Price/Sales (5.01), Price/Book (5.73) suggest expensive pricing. Growth concerns include Revenue Growth at 11.40%, which may limit upside. Profitability pressure is visible in Profit Margin at 12.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 15.10% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 11.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (EPS Growth, Institutional Own.) and negatives (Price/Book, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SYK Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SYK's Price-to-Sales ratio of 5.01x trades at a 36% premium to its historical average of 3.69x (89th percentile). The current valuation is 11% below its historical high of 5.65x set in Mar 2026, and 151% above its historical low of 2x in Feb 2009. Over the past 12 months, the PS ratio has compressed from ~5.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Stryker Corporation (SYK) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Stryker Corporation operates as a stable business with moderate growth and solid fundamentals. Revenue reached 25.1B with 11% growth year-over-year. Profit margins of 12.9% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 1.9B in free cash flow and 2.1B in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Stryker Corporation push profit margins above 15% as the business scales?
Debt management: total debt of 14.9B is significantly higher than cash (4.0B). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Stryker Corporation.
Bottom Line
Stryker Corporation offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Stryker Corporation(SYK)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.